The warning, label by label
Each label says acute kidney injury has been reported in people taking the medicine, in some cases needing hemodialysis, and that most reports involved people who had become dehydrated after nausea, vomiting or diarrhea [1][2][3][4][5][6]. The tirzepatide and orforglipron labels phrase this as reports with GLP-1 medicines as a group or with their own product [3][4][6]. Brand pages such as the Ozempic®, Mounjaro® and Zepbound® kidney articles go into each label’s detail; the table below compares them.
- Post-marketing reports come from a population of unknown size, so they cannot give a rate or prove cause [2].
- Volume depletion means the body has lost too much fluid; the warning sits next to the stomach side effects for that reason.
| Document | Section | What it reports |
|---|---|---|
| Ozempic®, US label [2] | 5.6; 6.2 | Post-marketing reports; listed among post-approval reactions |
| Wegovy®, US label [1] | 5.5; 6.1 | 7 adults on Wegovy® vs 4 on placebo in weight trials (0.4 vs 0.2 cases per 100 patient-years) |
| Mounjaro®, US label [3] | 5.5; 8.6 | Post-marketing reports; kidney checks at start and dose increases in kidney impairment with severe stomach reactions |
| Zepbound®, US label [4] | 5.3; 6.1 | 0.5% vs 0.2% on placebo in two weight trials |
| Saxenda®, US label [5] | 5.6; 8.6 | Post-marketing reports; limited experience in kidney impairment |
| Foundayo™, US label [6] | 5.4; 6.1 | 0.2% vs 0.05% on placebo in two trials |
| Ozempic®, EU product information [8] | 4.4 | Dehydration may, in rare cases, worsen kidney function |
| Mounjaro®, EU product information [9] | 4.4 | Dehydration could worsen kidney function, including acute renal failure |
| Zepbound®, Canadian monograph [10] | 8 | Acute kidney injury among post-marketing reports |
When the labels watch most closely
Every label asks prescribers to check kidney function in people who report side effects that could lead to fluid loss, particularly when treatment starts and when the dose goes up [1][2][3][4][5][6]. Those are also the weeks when nausea and vomiting tend to be most common.
The Wegovy® label adds that kidney adverse reactions were more likely in adults with a history of kidney impairment, and happened more often during dose titration; two more people in other trials had kidney injury with dehydration [1]. The Mounjaro® label says no dose change is needed for kidney impairment, but asks for kidney checks when starting or increasing the dose in people with kidney impairment who report severe stomach reactions [3].
What studies report
- FAERS pharmacovigilance, Dong 2022: about 2,700 reports of kidney injury with GLP-1 medicines up to 2021, most often liraglutide, with a median of about two months from start to onset [12]. Spontaneous reports show a signal, not a rate or a cause, and newer medicines such as tirzepatide were not included.
- Network meta-analysis of randomised trials, Liang 2026: across 67 trials and nearly 200,000 participants, only the higher tirzepatide doses tested were linked to more kidney injury than control, an absolute difference of about 0.3%; no other GLP-1 medicine showed a significant increase [13]. Trials report kidney injury in different ways, which limits pooled comparisons.
- Case series, Begum 2024: two people on semaglutide developed biopsy-proven kidney inflammation (acute interstitial nephritis) that improved after stopping the medicine and treatment [7]. Case reports describe single patients and cannot establish cause, but they show not every kidney problem on a GLP-1 is from dehydration [7].
Why it may happen
- Supported by the labels: nausea, vomiting and diarrhea lead to fluid loss, and dehydration then reduces kidney function [1][8][9]. The Wegovy® and Zepbound® labels also report low blood pressure linked to stomach side effects and dehydration: hypotension in 1.3% vs 0.4% and fainting in 0.8% vs 0.2% with Wegovy®, and hypotension in 1.6% vs 0.1% with Zepbound® [1][4].
- Proposed but not measured: an immune-type kidney inflammation, described in a few case reports with semaglutide, is a separate route that does not depend on fluid loss [7].
- General: MedlinePlus lists very low blood pressure from dehydration as one cause of sudden kidney failure, because blood flow to the kidneys falls [14]. Eating and drinking less while nauseated also adds to fluid loss [15].
What else could it be
Kidney function can drop for many reasons that have nothing to do with a GLP-1 medicine. MedlinePlus lists infections, a blockage in the urinary tract, blood clots in kidney vessels, and medicines including non-steroidal anti-inflammatory painkillers, certain antibiotics and blood pressure medicines, and contrast dye [14]. Diuretics and uncontrolled diabetes can also cause fluid loss through urine [15].
Pain in the side or back with blood in the urine may point to a stone rather than dehydration; the kidney stones article covers that separately. If you take pain relievers for aches or headaches while on treatment, a pharmacist can tell you which ones are easier on the kidneys.
Kidney disease and Ozempic®’s kidney approval
The Ozempic®, Mounjaro® and Zepbound® labels say no dose adjustment is recommended for kidney impairment, because kidney function did not meaningfully change how the medicine is handled [2][3][4]. The Saxenda® label notes limited experience in kidney impairment [5].
Ozempic® is also approved to lower the risk of lasting eGFR decline, end-stage kidney disease and death from heart disease when an adult has both type 2 diabetes and chronic kidney disease [2]. In the FLOW trial of 3,533 people, major kidney events were 24% less likely on semaglutide than placebo, and serious adverse events were slightly less common [11]. The label says FLOW found no new serious or severe adverse reactions [2]. The Ozempic® kidney indication article explains that approval in full; it and the dehydration warning sit side by side in the same label.
What may help
The labels ask prescribers to explain how to avoid fluid loss and which kidney signs to report, and ask patients to report nausea, vomiting or diarrhea that keeps going [1][4][6]. The EU Ozempic® leaflet says drinking plenty of fluids matters most if you already have kidney problems [8].
MedlinePlus suggests sipping water, or drinks with electrolytes, when dehydrated, and advises against salt tablets [15]. It also says that anyone vomiting or with diarrhea should keep drinking without waiting for signs of dehydration, and should call a provider if they think dehydration is coming [15]. How much is right for you, especially with kidney or heart disease, is a question for your prescriber; the hydration article has more.
Ozempic®, Wegovy® and Saxenda® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks and Foundayo™ is a trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Novo Nordisk or Eli Lilly and Company.
When to get help
| Sign | Who to contact | How fast | Source |
|---|---|---|---|
| Not passing urine, very dark urine, confusion, fainting or a racing heart during vomiting or diarrhea | Emergency care | Emergency | MedlinePlus Dehydration [15] |
| Urine output slowing or stopping, or new swelling in the legs, ankles or feet | Your prescriber or urgent care | Today | MedlinePlus Acute kidney failure [14] |
| Nausea, vomiting or diarrhea that will not stop, or little fluid kept down | Your prescriber | Today | Wegovy® and Zepbound® labels [1][4] |
| Dizziness or light-headedness on standing, with stomach symptoms | Your prescriber | Today | Wegovy® and Zepbound® labels [1][4] |
| Known kidney disease before starting or before a dose increase | Your prescriber, to plan kidney checks | At your next appointment | Wegovy® and Mounjaro® labels [1][3] |
